Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate
Stefan Harmsen(Utrecht University), Robbert J. Kok(Utrecht University), M. Emmy M. Dolman(Cancer Institute of New South Wales), Bálint Szokol(Vichem Chemie (Hungary)), M. Lacombe(Université du Québec à Rimouski), László Őrfi, János Pató(Vichem Chemie (Hungary)), Gÿorgý Kéri(Semmelweis University), Zoltán Nemes(Utrecht University), Gert Storm(Yong In University), Wim E. Hennink(Utrecht University)
Cited by 20
Related Papers
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
|Nature Genetics|2015|563
Sheddable Coatings for Long-Circulating Nanoparticles
|Pharmaceutical Research|2007|549
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396